Nicholas Piramal posted all round performance during the quarter ended December 2006 with significant growth in bottom line. The net profit went up by 82.5 per cent to Rs 43.3 crore from Rs 23.74 crore in the corresponding period of last year. The net sales increased by 14.3 per cent to Rs 408.03 crore from Rs 356.89 crore. The earning per share improved to Rs 2 from Rs 1.1 in the last period.
As per the BSE figures, the consolidated net profit increased sharply to Rs 55.55 crore from Rs 9.68 crore in the similar period of last year. Its net income touched to Rs 649.70 crore as compared to Rs 406.02 crore in the last period. The consolidated results for the current quarter ended December 31, 2006 include the results of NPIL Pharmaceuticals (UK) Ltd, UK and Torcan Chemicals Ltd, Canada which were acquired in December 2005 and the Morpeth facility acquired from Pfizer in June 2006. The figures therefore are not strictly comparable.